Shots:

• The P-III NAVIGATOR study involves assessing Tezepelumab + SOC vs PBO + SOC in adults (18–80 yrs.) & adolescents (12–17 yrs.) with severe uncontrolled asthma
• The results demonstrate superiority in 1EP & 2EP in a broad population i.e.- 77% reduction in AAER with blood eosinophil counts (≥300 cells/ microlitre) and FeNO levels (≥25 parts/ billion)- 85% reduction in exacerbations that require hospitalizations @52 wks. The pre-specified exploratory analyses showed reductions in AAERs @52 wks. in the overall patient population
• Final results from the PATHFINDER clinical trial programme will be presented further at ATS in coming wks.- including the primary analyses from P-III SOURCE & P-II CASCADE II trials

  Ref: AstraZeneca | Image: AstraZeneca